Novartis AG
π¨πSwitzerland
- Country
- π¨πSwitzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 355
- Registration Number
- NCT00219167
- Locations
- π¨π
Novartis Pharmaceuticals, Basel, Switzerland
Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1797
- Registration Number
- NCT00219180
- Locations
- πΊπΈ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients
Phase 3
Completed
- Conditions
- DiabetesHypertension
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 336
- Registration Number
- NCT00219102
- Locations
- πΊπ¦
Investigative Site, Kiev, Ukraine
π¨πNovartis Pharmaceuticals, Basel, Switzerland
An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
Phase 3
Completed
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 868
- Registration Number
- NCT00219232
Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 2775
- Registration Number
- NCT00219024
- Locations
- πΊπΈ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 504
- Registration Number
- NCT00219076
- Locations
- πΊπΈ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Clinical Study to Compare the Safety and Efficacy of an Aliskiren-based Regimen With a Lisinopril Based Regimen in Patients With Severe Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-02-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 180
- Registration Number
- NCT00219050
- Locations
- πͺπΈ
Investigative Site, Madrid, Spain
π¨πNovartis Pharmaceuticals, Basel, Switzerland
RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir
Phase 4
Completed
- Conditions
- Recurrent Genital Herpes (RGH)
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Novartis
- Registration Number
- NCT00219310
- Locations
- πΊπΈ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
An Extension Study Evaluating the Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits
Phase 4
Completed
- Conditions
- Traumatic Brain Injury With Persistent Cognitive Deficits
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 157
- Registration Number
- NCT00219245
Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1955
- Registration Number
- NCT00219037